Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis

Conditions

Idiopathic Pulmonary Fibrosis

What is the purpose of this trial?

To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.


Participation Guidelines

Age:
40 Years - 80 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
FibroGen, Inc
Dates:
04/18/2013
Last Updated:
Study HIC#:
1303011684